TY - JOUR
T1 - Expression of the anaphylatoxin C5a receptor in gastric cancer
T2 - implications for vascular invasion and patient outcomes
AU - Nitta, Hidetoshi
AU - Shimose, Takayuki
AU - Emi, Yasunori
AU - Imamura, Takahisa
AU - Ohnishi, Koji
AU - Kusumoto, Tetsuya
AU - Yamamoto, Manabu
AU - Fukuzawa, Kengo
AU - Takahashi, Ikuo
AU - Higashi, Hidefumi
AU - Tsuji, Akihito
AU - Akagi, Yoshito
AU - Oki, Eiji
AU - Maehara, Yoshihiko
AU - Baba, Hideo
AU - Kyushu Study Group of Clinical Cancer (KSCC) ancillary study, Study Group of Clinical Cancer (KSCC) ancillary study
N1 - Funding Information:
The authors are indebted to the physicians and all other medical staff. We also thank Ms. Sakamoto and the staff in the Clinical Research Support Center Kyushu (CReS Kyushu) for their excellent data collection and management, secretarial assistance, and support. We also thank Ms. Tatsuko Kubo for technical assistance of immunohistochemical staining. This study was conducted by the Kyushu Study Group of Clinical Cancer and CReS Kyushu. Chugai Pharmaceutical, Yakult Honsha, Takeda Pharmaceutical, Merck Serono, and Taiho Pharmaceutical have provided an unrestricted contribution to CReS Kyushu. This work was supported in part by the Japan Society for the Promotion of Science (JSPS) Grant-in-Aid for Scientific Research, Grant Number 25462009.
Publisher Copyright:
© 2016, Springer Science+Business Media New York.
PY - 2016/11/1
Y1 - 2016/11/1
N2 - The C5a receptor (C5aR) expressed in various types of cancers is involved in C5a-induced cancer cell invasion. However, its role in gastric cancer has not yet been fully elucidated. Therefore, we studied the clinical significance of C5aR expression in gastric cancer. The association of C5aR expression in gastric cancer, determined by immunostaining using the anti-C5aR antibody, with clinicopathological parameters and outcomes was evaluated in 148 patients. Further, the association of C5aR expression in liver metastatic sites with clinicopathological parameters was investigated in a separate cohort of 58 patients who underwent hepatectomy. High tumoral C5aR expression (n = 45, 30.4 %) was significantly related to tumor location, cancer invasion depth, vascular and lymphatic invasion, and tumor stage. The 5-year recurrence-free and overall survival rates of patients with high tumoral C5aR expression were significantly lower than those of patients with low tumoral C5aR expression (50.9 vs. 84.2 %, P = 0.002 and 58.8 vs. 86.1 %, P = 0.007, respectively). The incidence of liver metastasis was significantly higher in patients with high tumoral C5aR expression (13.3 %) than in those with low tumoral C5aR expression (3.9 %; P = 0.04). C5aR expression at liver metastatic sites was associated with the C5aR expression status at the primary site (P = 0.0004), vascular invasion at the primary site (P = 0.04), and tumor size at the metastatic site (P = 0.01). C5aR expression in gastric cancer was associated with cancer progression, liver metastasis, and poor prognosis. Therefore, C5aR may represent a prognostic factor and therapeutic target in gastric cancer.
AB - The C5a receptor (C5aR) expressed in various types of cancers is involved in C5a-induced cancer cell invasion. However, its role in gastric cancer has not yet been fully elucidated. Therefore, we studied the clinical significance of C5aR expression in gastric cancer. The association of C5aR expression in gastric cancer, determined by immunostaining using the anti-C5aR antibody, with clinicopathological parameters and outcomes was evaluated in 148 patients. Further, the association of C5aR expression in liver metastatic sites with clinicopathological parameters was investigated in a separate cohort of 58 patients who underwent hepatectomy. High tumoral C5aR expression (n = 45, 30.4 %) was significantly related to tumor location, cancer invasion depth, vascular and lymphatic invasion, and tumor stage. The 5-year recurrence-free and overall survival rates of patients with high tumoral C5aR expression were significantly lower than those of patients with low tumoral C5aR expression (50.9 vs. 84.2 %, P = 0.002 and 58.8 vs. 86.1 %, P = 0.007, respectively). The incidence of liver metastasis was significantly higher in patients with high tumoral C5aR expression (13.3 %) than in those with low tumoral C5aR expression (3.9 %; P = 0.04). C5aR expression at liver metastatic sites was associated with the C5aR expression status at the primary site (P = 0.0004), vascular invasion at the primary site (P = 0.04), and tumor size at the metastatic site (P = 0.01). C5aR expression in gastric cancer was associated with cancer progression, liver metastasis, and poor prognosis. Therefore, C5aR may represent a prognostic factor and therapeutic target in gastric cancer.
UR - http://www.scopus.com/inward/record.url?scp=84989359850&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84989359850&partnerID=8YFLogxK
U2 - 10.1007/s12032-016-0834-9
DO - 10.1007/s12032-016-0834-9
M3 - Article
C2 - 27688239
AN - SCOPUS:84989359850
SN - 1357-0560
VL - 33
JO - Medical Oncology
JF - Medical Oncology
IS - 11
M1 - 118
ER -
